To study different etiological and prognostic factors in patients suffering from ARDS/ALI

Praveen Subhash Chabukswar1*, Jaya Bhaskar Baviskar2

1,2Assistant Professor, 1Dept. of Chest & TB, 2Dept. of Pathology, Indian Institute of Medical Science & Research, Jalna, Maharashtra, India

*Corresponding Author: Praveen Subhash Chabukswar
Email: prvchbkswr@gmail.com

Abstract
Background: Acute inflammatory reaction in the lung which causes injury to the endothelial cells and alveolar epithelium are main pathological changes that may occur in ARDS. This leads to pulmonary edema which eventually causes respiratory failure in these patients. Multiple organ dysfunction syndrome (MODS) is common consequence in these patients. Mortality rate corresponds to the severity of underlying disease and it ranges from 10% to 90%.

Methodology: All patients were screened for the diagnostic criteria of ARDS as per the 1994 American European Consensus Conference on ARDS/ALI. Different scores suggesting outcome were calculated on admission to intensive care unit. Objectives of study were [1] To identify the different risk factors responsible for ARDS/ALI, [2] To study the lung functions in ARDS/ALI survivors, [3] To analyze the effect of treatment strategies on lung functions in survivors, [4] To study different scoring systems.

Results: In our study we had a total of 65 patient, out of which 35 survived. The risk factors for developing ALI/ARDS were pneumonia, tropical diseases, postoperative sepsis, poly trauma, tuberculosis, malignancy, poisoning and neurological disorder.

Conclusions: Pneumonia and tropical diseases are the common risk factor for the ARDS/ALI. The presence of co-morbid conditions also affects the outcome of ALI/ARDS patients. MODS of >4, LIs >2 and APACHE II >2 had associated with higher mortality.

Keywords: ARDS; ALI; Pneumonia.

Introduction
Acute respiratory distress syndrome (ARDS) is common outcome in patients with critical underlying diseases. Acute inflammatory reaction in the lung which causes injury to the endothelial cells and alveolar epithelium are main pathological changes that may occur in ARDS. This leads to pulmonary edema which eventually causes respiratory failure in these patients [1]. Disease with lesser severity is known as acute lung injury (ALI). In ARDS there is increased micro vascular permeability localized to the lung secondary to generalized inflammatory disorder termed as systemic inflammatory response disorder (SIRS) [2-4]. Although an increase in vascular permeability and subsequent interstitial and air space edema are initially major consequences of the acute inflammatory response, the injury involves severe damage to endothelial cells in multiple organs especially in the setting of sepsis and trauma. If the patient survives the consequences of pulmonary edema, manifestations of other systems dysfunction soon appear resulting in multi organ dysfunction syndrome (MODS) [4,5].

Sepsis, gastric aspiration, lung contusion, massive transfusion of blood, pneumonia, and major trauma are the common causes of ARDS/ALI [6]. Several attempts made to define ARDS/ALI which would be useful in clinical management [7]. Different scoring systems have been devised for determining outcome and planning further management. The newer modalities of treatment that aim at providing improving gas exchange and preventing structural lung injury due to the ventilator are commonly used. These include the use low tidal volumes, the application of high levels of positive end-expiratory pressure (PEEP), permissive hyper apnea, cyclic prone positioning and nitric oxide inhalation. Other measures include surfactant therapy, liquid ventilation, extra corporeal membrane oxygenation (ECMO),

All these treatment modalities aim at not only to reduce the mortality but also the long-term effects of mechanical ventilation in survivors. Some of the survivors have persistent impairment because of ventilator defects, bronchial hyper reactivity, impaired diffusing capacity of the lung for carbon monoxide (DLCO), and a drop in PaO2 during exercise. The mortality rates of ARDS/ALI are generally reported to exceed 50% and range from 10 to 90% depending on the etiology, severity, definition of ALI/ARDS, and the presence of pre-existing disease [8-11]. So this study was planned to find out the factors affecting or predict the outcome of disease and to evaluate different treatment modalities in the management of patients with ARDS/ALI.

Materials and Methods
This was a prospective cohort (analytical epidemiology) study conducted in compliance with the protocol, after Institutional Ethics Committee (IEC) approval, informed consent regulations, as per Declaration of Helsinki and the ICMR guidelines for Biomedical Research on Human Subjects. All the survived cases of ARDS/ALI attending tertiary health care center in the year of 2008 were enroll in the study. All patients were screened for the diagnostic criteria of ARDS according to American European consensus definition (1994). Patients with diagnosis of ARDS/ALI having age more than 12 years and willing to take part in the study and given consent were recruited. Patients having contraindications for Pulmonary function test, history of recent myocardial infarction and active hemoptysis were excluded from the study. All patients willing to participate and give an informed consent were screened for eligibility. Baseline evaluation included recording of demographic details, medical history, general and systemic examination, and laboratory investigations, which included complete
Results
In our study we had a total of 65 patient, out of which 35 survived. We had a mortality rate of 46.2%. The mean age of the patients in our study was 33.37 (±15.14) years in survivors and 39.40 (±15.49) years in the non-survivors. The risk factors for developing ALI/ARDS were pneumonia (21 patients), tropical diseases (15 patients), postoperative sepsis (8 patients), poly trauma (8 patients), tuberculosis (6 patients), malignancy (3 patients), poisoning (2 patients) and neurological disorder (2 patients).

Discussion
The ARDS is a disease with a high mortality and is a common cause of admission into intensive care units (ICUs) all over the world [15-18]. The American-European Consensus Conference definition of ALI and ARDS was published in 1994. This definition is simple to apply in the clinical setting and also recognizes that the severity of clinical lung injury varies according to the severity of arterial hypoxemia [19].

The risk factors for developing ALI/ARDS in our study were Pneumonia (32.3%), Tropical diseases (23.07%), Postoperative sepsis (12.3%), Poly trauma (12.3%), Tuberculosis (9.2%), Malignancy (4.6%), Poisoning (3.1%) and Neurological disorder (3.1%). In the study by Vigg et al., [20] the common risk factors for ALI/ARDS were pneumonia (30%), recent surgery in abdomen (10%), sepsisemia with MOF (18%), and trauma (12%). Other significant causes were pancreatitis, thermal burns > 40% (6%), peritonitis, falciparum malaria and poisoning. Similar findings were also find in the studies by Zilberberg et al., [21]. When compared with the risk factor associated with the non-survivors in our study, it is observed that the most common risk factor is pneumonia and that the incidence of sepsis, poly trauma is quite similar in both the studies however the incidence of tropical diseases is much higher in our study.

The presence of co-morbid conditions also affects the outcome of ALI/ARDS patients. In our study 15% of the patients had respiratory diseases, 7.7% of the patients had hypertension, 6.2% of the patients had diabetes mellitus, 3% of the patients had HIV and 1.5% of the patients had ischemic heart disease. It was observed that 18.5% of the patients used to consume alcohol. However none of the above factors affected the outcome of the patients significantly. In the study by Silberberg et al., [21] it was observed that cirrhosis of the liver (20%), HIV infection (10%), active malignancy (24%) and organ transplantation (9%) were the common co-morbid conditions in the patients dying due to ALI/ARDS. In the study by Vigg et al., [20] 20% of the patients had hypertension, 8% of the patients had diabetes mellitus and 3% of the patients had coronary artery disease. The low incidence of the co-morbid conditions like malignancy, HIV infection in our study could represent a lack of awareness and early detection of these conditions in the general population.

An attempt was made to analyze the presenting clinical features of the patient and the impact they had on the outcome. It was observed that most of the patients presented within 10 days of the onset of the symptoms. Fever was seen in majority of patients with duration of 2 to 4 days. History of wading through water was present in 27(73%) cases, this can be attributed to the similar frequency of leptospirosis 22(59.5%) which is water borne infection. 11(29.7%) patients had history of hemoptysis. Duration of cough related with the outcome of disease. Prognosis was better in patients with duration of cough less than 10 days. Hence early detection of symptoms like cough could alter the outcome of the disease.

Systemic abnormalities were found in majority of cases in the form of hematological, renal and liver dysfunction. These finding in our study show similar pattern as in the study carried out by Zilberberg et al., [21]. In a study by Fallow et al., [22] renal and Hematological dysfunction have been shown to be independent predictors of mortality. The organisms that were commonly isolated in cultures (blood and sputum) were pseudomonas and Klebsiella. A similar organism’s pattern was seen in patient’s studies by Vigg et al., [20].

A number of studies had found a direct association between poor oxygenation and mortality whereas other studies have failed to identify a correlation [23-26]. When tested prospectively, increasing severity of lung injury (using LIS Score), measured at 24, 48, and 72 hours, wasn’t associated with increased mortality [26]. We also observed that a MODS of >4, LIS >2 and APACHE II >2 had higher association with mortality. The mean score in non-survivors were as follows: MODS 5.3, LIS 2.3 and APACHE II 17.6 these scoring systems were equally effective in predicting mortality in ALI/ARDS due to tropical diseases. The SOFA score was not found to be useful in predicting the outcome. It should be noted that we had used the scores only during assessment of the patients on the first day of admission in our ICU. The mean P/F ratio was 208 in survivors and 167 in non-survivors in our study. However no significant difference has been found in the P/F ratio in survivors and non-survivors in other studies [21,26].
In our study 60% of the patients required mechanical ventilation. The patients were ventilated using ACMV (Assist control mechanical ventilation) or control mode and a lung protective strategy with tidal volume of 8ml/kg was given with PEEP whenever required. Inverse ratio ventilation and prone pressure ventilation were also attempted in a few cases. The significant finding was that survivors spent lesser number of days (mean 2.74 days) on ventilator than non-survivors (mean 8.73 days). Also 50% of the deaths were within the first 24 hours. In the study by Vigg et al., [20] duration of ventilation was less than 7 days in 80% of the patients (dead) while the same was 66% in non-survivors in our study and 71% in survivors. The use of steroids in our study did not reduce the mortality as in other studies [27,28]. In the survivors a PFT was done in 34% of the patients. It was seen that overall 43% has an obstructive and restrictive pattern 28.5% had an obstructive pattern and 28.5% had a normal PFT. It was also seen that none of these patients had preexisting respiratory disease. Mean pO2 on discharge was 81 mm of Hg so a long-term prospective trial is essential to look at the long-term effects of ALI/ARDS patients in the survivors of this condition.

**Conclusions**

Pneumonia and tropical diseases are the common risk factor for the ARDS/ALI. The presence of co-morbid conditions also affects the outcome of ALI/ARDS patients. MODS of >4, LIs >2 and APACHE II >2 had associated with higher mortality.

**Table 1:** Demographic and clinical details of patients with ARDS/ALI (both survivors and non survivors)

| Parameter                        | Alive Patients In numbers | Dead Patients In numbers |
|----------------------------------|---------------------------|-------------------------|
| Age (in years)                   |                           |                         |
| <25                              | 14                        | 4                       |
| 25-60                            | 17                        | 23                      |
| >60                              | 4                         | 3                       |
| Sex                              |                           |                         |
| Male                             | 21                        | 23                      |
| Female                           | 14                        | 7                       |
| Diagnosis                        |                           |                         |
| Pneumonia                        | 12                        | 9                       |
| Post-operative sepsis            | 4                         | 4                       |
| Poly trauma                      | 4                         | 4                       |
| Carcinoma                        | 0                         | 3                       |
| Neurological Disorder            | 1                         | 1                       |
| TB                               | 6                         | 0                       |
| Poisoning                        | 1                         | 1                       |
| Tropical diseases                |                           |                         |
| Leptospirosis                    | 3                         | 3                       |
| Malaria                          | 2                         | 0                       |
| Dengue                           | 1                         | 0                       |
| Malaria + Leptospirosis          | 1                         | 0                       |
| Undiagnosed                      | 0                         | 5                       |
| Time since onset                 |                           |                         |
| <10days                          | 24                        | 19                      |
| >10days                          | 11                        | 11                      |
| Fever                            |                           |                         |
| No                               | 7                         | 2                       |
| <8days                           | 28                        | 28                      |
| Cough                            |                           |                         |
| No                               | 10                        | 8                       |
| <8days                           | 21                        | 9                       |
| >8days                           | 4                         | 13                      |
| Breathlessness                   |                           |                         |
| No                               | 3                         | 6                       |
| <8days                           | 24                        | 14                      |
| >8days                           | 8                         | 10                      |
| Bleeding                         |                           |                         |
| Yes                              | 4                         | 4                       |
| No                               | 30                        | 26                      |
| Epistaxis                        | 1                         | 0                       |
| Tuberculosis                     |                           |                         |
| Yes                              | 3                         | 0                       |
| No                               | 32                        | 30                      |
| Ischemic heart disease           |                           |                         |
| Yes                              | 1                         | 2                       |
| No                               | 34                        | 27                      |
| Respiratory disease | COPD | 1 | 0 |
|---------------------|------|---|---|
| Byssinosis          |      | 1 | 1 |
| Bronchiectasis      |      | 1 | 3 |
| Bulla               |      | 0 | 1 |
| Nil                 |      | 32| 0 |
| Hypertension        | Yes  | 2 | 3 |
| No                  |      | 33| 28|
| diabetes mellitus   | Yes  | 2 | 2 |
| No                  |      | 33| 22|
| Smoker              | Yes  | 6 | 8 |
| No                  |      | 29| 23|
| Alcoholic           | Yes  | 5 | 7 |
| No                  |      | 30| 11|
| Temperature °C      |      | 37.20| 37.09|
| Pulse (/min)        |      | 108| 116|
| Respiratory rate (/min) | 34 | 38|
| Glasgow coma scale  |      | 13| 12|
| Pallor              | Yes  | 15| 5 |
| No                  |      | 20| 25|
| Cyanosis            | Yes  | 3 | 27|
| No                  |      | 32| 3 |
| Skin Rash           | Yes  | 35| 27|
| No                  |      | 0 | 3 |
| Platelets in lacks  |      | 2.1| 1.6|
| PT/APTT             | Normal| 1| 13|
|                     | Deranged| 34| 17|
| DIC                 | Yes  | 8 | 11|
| No                  |      | 27| 19|
| Liver dysfunction   | Absent| 11| 16|
| Present             |      | 24| 14|
| Renal dysfunction   | Absent| 14| 11|
| Present             |      | 21| 19|
| P/F ratio           |      | 208| 167|
| SOFA                | <5   | 19| 11|
| >5                  |      | 16| 19|
| MODS                | <4   | 21| 8 |
| >4                  |      | 14| 22|
| LIS                 | <2   | 14| 5 |
| >2                  |      | 21| 25|
| APACHE II           | <12  | 19| 6 |
| >12                 |      | 16| 24|
| Steroids taken      | Yes  | 3 | 6 |
| No                  |      | 32| 24|
| Days on ventilator  |      | 3 | 9 |

APTT: Activated Partial Thromboplastin time; PT: prothrombin Time; DIC: disseminated intravascular coagulation; P/F: SOFA Score: Sequential Organ Dysfunction Assessment; MODS: Multiple Organ Dysfunction score; LIS: lung injury score; APACHE: Acute Physiology and Chronic Health Evaluation.

Conflicts of Interest: None declared.

Acknowledgements: Nil.

References
1. Atabai K, Matlhay MA. Acute lung injury and acute respiratory distress syndrome: definitions and epidemiology. *Thorax* 2002:57:452-8.
2. Hyers TM, Gee M, Andreadis NA. Cellular interactions in multiple organ injury syndrome. *Am Rev Respir Dis* 1987;135(4):952-3.
3. Renaldo Jest Chrisman JW. Mechanisms and mediators of adult respiratory distress syndrome. *Cline Chest Med* 1990;11:621.
4. Bone CT Balk RA, Cierra Fats. ACCP SCCM consensus conference: Definition for sepsis and organ failure and guidelines for the use of innovative therapies in Sepsis. Chest 1991;101:1644.
5. Montgomery BR, Stager MA, Carrick CJ, Hudson LD: Causes of mortality in patients with the adult Respiratory distress syndrome. Am Rev Respir Dis 1985:132:484.
6. Neff Thomas A, Stocker Recto, Frey Hans-Rudolf, Stein Sonja, Russia Erich W. Long-term Assessment of Lung Function in Survivors of Severe ARDS. Chest 2003:123:845-53.
7. Arabia K, Mathai MA. Acute lung injury and acute respiratory distress syndrome: definitions and epidemiology. Thorax 2002;57:452-8.
8. Artigas A, Carlit J, Legal JR, Chastang CJ, Blanch L, Fernandez K, et al. Clinical presentation, prognostic factors, and outcome of ARDS in the European Collaborative Study (1985-1987): preliminary report. In W. Zimpel and F. Lemaitre, editors. Adult Respiratory Distress Syndrome. Marcel Dekker 1991:50:37-63.
9. Kraft P, Fredric P, Pemerstorfer T. The acute respiratory distress syndrome: definitions, severity and clinical outcome: an analysis of 101 clinical investigations. Intensive Care Med 1996;22:519-29.
10. Jardin F, Fellahin JL, Beached A. Improved prognosis of acute respiratory distress syndrome 15 years on. Intensive Care Med 1999;25:936-41.
11. Eisner MD, Thompson T, Hudson LD. Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164:231-6.
12. Ray P. Protection of epithelial cells by keratinocyte growth factor signaling. Proc Am Thorac Soc 2005;2(3):221-5.
13. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114(9):1308-16.
14. Cornet AD1, van Nieuw Amerongen GP, Beishuizen A, Schultz MJ, Girbes AR, Groeneveld AJ. Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Drug Discov 2009;4(3):219-27.
15. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. International Surviving Sepsis Campaign Guidelines Committee. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock 2008. Crit Care Med 2008;36:296–327.
16. Sharma SK, Mohan A. Acute respiratory distress syndrome. In: Grover A, Aggarwal V, Gera P, Gupta R, editors. Manual of medical emergencies. 3rd edn. Delhi: Pushpanjali Medical Publishers 2007:396–402.
17. Sharma SK, Mohan A. Acute respiratory distress syndrome. In: Manoria PC, editor. Postgraduate medicine. Mumbai: Assoc Physicians India. 2005:19:135–51.
18. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007;369:1553–64.
19. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818–24.
20. Vigg A, Mantri S, Vigg Avanti, Vigg A: Clinical profile of ARDS. JAPI 2003;51:855-8.
21. Zilberberg MD, Epstein SK. Acute lung injury in the medical ICU: comorbid conditions, age, etiology, and hospital outcome. Am J Respir Crit Care Med 1998;157:1159-64.
22. Fallow L, Vera SR, Fernandez AK, Silva DR, Rossetti MC, Acute lung injury and adult respiratory distress syndrome at the intensive care unit of a general university hospital in Brazil. An epidemiological study using American-European Consensus Criteria. Intensive Care Med 2002;28(11):1644-8.
23. Milberg JA, Davis DR, Steinberg KP, Hudson LD. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983–1993. JAMA 1995;273(4):306–9.
24. Sloane PJ, Gee MH, Gottlieb JE, et al. A multicenter registry of patients with acute respiratory distress syndrome. Physiology and outcome. Am Rag Respir Med 1992:146:419-26.
25. Suchyta, MR., Calmer TP, Elliott CG, Orem JF Jr, Weaver L. The adult respiratory distress syndrome: a report of survival and modifying factors. Chest 1992;101:1074-9.
26. Doyle RL, Szafiarski N, Morin GW. -Evener- Cornish JF MA. Identification of patients with acute lung injury: predictors or mortality. Am J Respir Crit Care Med 1995;152:1818-24.
27. Ice JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchyma lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988;136:62-68.
28. Sprung Cl, Carli’s PV, Marcia EH. The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study. N Engle J Med 1984;311:1137-43.

How to cite this article: Chabukswar PS, Baviskar JB. To study different etiological and prognostic factors in patients suffering from ARDS/ALI. Indian J Immunol Respir Med 2019;4(2):104-8.